Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKBKB | O14920 | 4/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.32 |
| ▸ | TOP2A | P11388 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10191699 | 0.89 | KDM4E (0.36) | KDM4EMEN1KMT2A | |
| SCHEMBL10191704 | 0.88 | IKBKB (0.43) | IKBKBKDM4EMEN1KMT2A | |
| SCHEMBL10191696 | 0.82 | KDM4E (0.39) | KDM4EMEN1KMT2A | |
| SCHEMBL10191680 | 0.82 | KDM4E (0.35) | KDM4EMEN1KMT2A | |
| SCHEMBL10191419 | 0.80 | HTR2C (0.41) | IKBKBKDM4EMEN1KMT2AAMY1A | |
| SCHEMBL10191692 | 0.74 | ALDH1A1 (0.43) | KDM4EMEN1KMT2A | |
| SCHEMBL10191409 | 0.70 | ELANE (0.46) | IKBKBKDM4E | |
| SCHEMBL10191734 | 0.68 | IGF1R (0.36) | — | |
| SCHEMBL10192463 | 0.68 | IGF1R (0.31) | — | |
| SCHEMBL10191416 | 0.68 | RECQL (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2595987-B1 | NEW AMINOPYRAZOLOQUINAZOLINES | BOEHRINGER INGELHEIM INT (DE) | 2018-04-18 | — | — | EP | disclosed |
| US-8735386-B2 | Aminopyrazoloquinazolines | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-05-27 | — | — | US | disclosed |
| US-8735386-B2 | Aminopyrazoloquinazolines | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-05-27 | — | — | US | disclosed |
| US-20120238542-A1 | AMINOPYRAZOLOQUINAZOLINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-09-20 | — | — | US | disclosed |
| US-20120238542-A1 | AMINOPYRAZOLOQUINAZOLINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-09-20 | — | — | US | disclosed |
| WO-2012010704-A1 | NEW AMINOPYRAZOLOQUINAZOLINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120238542-A1 | AMINOPYRAZOLOQUINAZOLINES | CCNT1, CCNI, MKI67 | IKBKB 2397/4885KDM4E 2540/4885MEN1 661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.